AME Company for Medical Supplies to pay SAR 14m dividends; governance updates announced
AME
9527 0.00% 73.00 0.00
Riyadh – Mubasher: AME Company for Medical Supplies’ shareholders approved a cash dividend distribution of SAR 14 million for the 2025 fiscal year, according to a bourse filing.
During an ordinary general meeting (OGM) held on 29 June 2026, the equityholders ratified the company’s financial statements and the adoption of several key governance frameworks aimed at strengthening the firm’s administrative structure.
A primary highlight of the OGM was the approval of the Board of Directors' recommendation to distribute cash dividends representing 20% of the company’s capital and translating to a dividend of SAR 2 per share for 2025.
According to the disclosure, eligibility for these dividends is restricted to shareholders who owned stock at the close of trading on the day of the assembly and who are registered in the company’s records at the Securities Depository Center (Edaa) by the end of the second trading day following the eligibility date.
The company confirmed that the disbursement process is scheduled to commence on 14 July 2026.
In addition to the dividend approval, shareholders reviewed and ratified the Board of Directors’ report and the audited financial statements for the 2025 fiscal year.
The assembly also formally discharged the members of the Board of Directors from liability for their activities during the same period and approved the auditor’s report.
The meeting also addressed executive compensation and internal governance. Shareholders approved the disbursement of SAR 853,333.64 as remuneration for the Board of Directors for the 2025 fiscal year.
Furthermore, the assembly passed several resolutions to update the company’s regulatory environment. These included amendments to the remuneration policy for board members and the adoption of revised work regulations for the Board of Directors, the Audit Committee, and the Nomination and Remuneration Committee.
These updates are intended to align the company’s internal controls with current regulatory standards and best practices in corporate governance.
Source: Mubasher Source: {{details.article.source}}